Related Experiment Video
Updated: May 25, 2026
03:38
Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
Published on: June 20, 2025
[Idiopathic pulmonary fibrosis -- progress in sight].
Riitta Kaarteenaho1, Ulla Hodgson, Marjukka Myllärniemi
1Oulun Yliopistollinen Sairaala, Medisininen Tulosalue, Keuhkosairaudet.
Duodecim; Laaketieteellinen Aikakauskirja
|February 11, 2012
Summary
This review covers the latest international guidelines for idiopathic pulmonary fibrosis (IPF), pirfenidone drug trials, and a new Finnish IPF patient register. The register aims to improve disease understanding and treatment standardization in Finland.
Area of Science:
- Pulmonology
- Clinical Trials
- Epidemiology
Context:
- Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited treatment options.
- International consensus and new therapeutic agents are emerging.
- Accurate disease prevalence data is crucial for resource allocation and research.
Purpose:
- To review the key elements of a new international statement on IPF.
- To discuss therapeutic trials involving pirfenidone, a novel IPF medication.
- To introduce a new Finnish IPF patient register and its potential applications.
Summary:
- The review outlines the latest international guidelines for IPF management.
- Pirfenidone is highlighted as a significant therapeutic development.
- A new Finnish IPF register is established to capture comprehensive patient data.
Impact:
- The Finnish IPF register aims to provide accurate disease prevalence data.
- Standardizing IPF diagnostics and treatment across Finland is a key objective.
- The register will facilitate future clinical trials and drug investigations for IPF.
Related Concept Videos
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:30Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...